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Abstract
Background: Prior studies suggest a role for a variant (rs5743836) in the promoter of toll-like receptor 9 (TLR9) in
asthma and other inflammatory diseases. We performed detailed genetic association studies of the functional
variant rs5743836 with asthma susceptibility and asthma-related phenotypes in three independent cohorts.
Methods: rs5743836 was genotyped in two family-based cohorts of children with asthma and a case-control study
of adult asthmatics. Association analyses were performed using chi square, family-based and population-based
testing. A luciferase assay was performed to investigate whether rs5743836 genotype influences TLR9 promoter
activity.
Results: Contrary to prior reports, rs5743836 was not associated with asthma in any of the three cohorts.
Marginally significant associations were found with FEV1 and FVC (p = 0.003 and p = 0.008, respectively) in one of
the family-based cohorts, but these associations were not significant after correcting for multiple comparisons.
Higher promoter activity of the CC genotype was demonstrated by luciferase assay, confirming the functional
importance of this variant.
Conclusion: Although rs5743836 confers regulatory effects on TLR9 transcription, this variant does not appear to
be an important asthma-susceptibility locus.
Background
Asthma is a public health problem of considerable
importance with over 300 million people affected world-
wide [1]. Asthma is likely due to genetic and environ-
mental determinants that are poorly understood.
Although primarily a disorder resulting from TH2 cell
mediated inflammation, significant interest is developing
in investigating innate immunity in the search to under-
stand the pathogenesis of this disease [2].
Toll-like receptors (TLRs) are evolutionarily conserved
components of the innate immune system that act to
directly recognize pathogen-derived elements, including
viral and bacterial DNA, lipopolysaccharides, and pro-
teoglycans. They provide a crucial link between the
recognition of pathogens by the innate immune system
and subsequent activation of adaptive immunity, indu-
cing maturation of antigen presenting cells and differen-
tiation of T cells. TLR9 is expressed in plasmacytoid
dendritic cells, B cells, CD3+CD4+ T cells and pulmon-
ary epithelial cells [3], and recognizes bacterial unmethy-
lated cytosine-guanine dinucleotide (CpG) motifs and
viral antigens [4]. When activated it leads to maturation
of dendritic cells and release of pro-inflammatory TH1
cytokines such as IL-6, IL-12, TNF, IFN-g and IFN-a. It
can also be counter-regulatory to the induction of T
regulatory cells (Tregs) and release of the anti-inflam-
matory cytokine IL-10.* Correspondence: renal@channing.harvard.edu1Channing Laboratory, Brigham and Women’s Hospital and Harvard Medical
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Our group and others have previously reported an
association between a single nucleotide polymorphism
(SNP) in the promoter region of TLR9 (rs5743836 or
-1237C/T) and asthma in European American adults [5]
and Tunisian children [6]. Other studies have shown
associations with other inflammatory diseases such as
allergic bronchopulmonary aspergillosis (ABPA) [7], ato-
pic eczema [8], and inflammatory bowel disease (IBD)
[9-11]. The observed associations between rs5743836
and various immune-mediated diseases in different
populations point to the possibility that this SNP may
be functional and potentially involved in immune system
regulation. Of interest, an interaction between TLR9 and
vitamin D has been implicated in the induction of Tregs
that produce IL-10 [12], an anti-inflammatory cytokine
with potent inhibitory effects on TH1 and TH2
responses[13].
Given previous findings, we sought to investigate the
possible association between SNP rs5743836 and asthma
in three different cohorts of asthmatics: the Childhood
Asthma Management Program (CAMP), the Genetics of
Asthma in Costa Rica study (Costa Rica), and the Infor-
matics for Integrating Biology to the Bedside (i2b2)
Crimson Asthma Project (iCAP). CAMP is a well-
characterized cohort of children from North America
with mild to moderate asthma in whom we have multiple
measures of lung function as well as data on exacerba-
tions, atopy and vitamin D levels. Because of the exten-
sive phenotyping in CAMP, we decided to probe more
deeply in this cohort by investigating possible associa-
tions with asthma-related quantitative phenotypes, and
to assess for interaction with vitamin D. In addition, we
performed functional studies in cell cultures to determine
potential functional significance of this SNP.
Methods
Population and phenotyping data
CAMP cohort
The Childhood Asthma Management program (CAMP)
is a multi-center, randomized, double-masked, placebo-
controlled clinical trial designed to investigate the long-
term effects of inhaled anti-inflammatory medications in
children with mild to moderate asthma [14,15]. Of the
1041 children enrolled in the original clinical trial, DNA
samples were obtained from 968 participating children
and 1518 of their parents. Due to the small sample size
of other ethnic groups, this analysis was restricted to
711 self-reported non-Hispanic white probands (n =
711) and available parents (n = 638 complete trios).
A diagnosis of asthma was based on methacholine
hyperreactivity (PC20 ≤ 12.5 gm/ml)and one or more
the following criteria for at least 6 months in the year
before recruitment: 1) asthma symptoms at least 2 times
per week, 2) at least 2 uses per week of an inhaled
bronchodilator, and 3) daily asthma medication. Spiro-
metry was performed according to American Thoracic
Society (ATS) recommendations [16] using a volume
displacement spirometer. Vitamin D levels (25-hydroxy-
vitamin D) from serum collected prior to treatment ran-
domization and at 44 months post-randomization were
measured using a radionimmunoassay method in
Dr. Bruce Hollis’ laboratory at the Medical University of
South Carolina [17,18]. The Institutional Review Board
of each of the CAMP study centers approved this study.
Informed assent and consent were obtained from all
study participants and their parents to collect DNA for
genetic studies.
Costa Rica cohort
Participants in the Costa Rica study included 616 chil-
dren ages 6-14 years with asthma (defined as physician-
diagnosed asthma and ≥ 2 respiratory symptoms or
recurrent asthma attacks in the past year) recruited
between February 2001 and March 2005, as previously
described [19]. This population is a genetic isolate of
mixed Spanish and Amerindian descent with one of the
world’s highest rates of asthma (27.4% of children aged
6-7 years) [20]. The study was approved by the Institu-
tional Review Boards of the Hospital Nacionál de Niños
(San Jose, Costa Rica) and Brigham and Women’s Hos-
pital (Boston, MA, USA). After obtaining written
informed consent from the parents of participating chil-
dren, each participant completed a modified version of
the questionnaire used in the Collaborative Study on the
Genetics of Asthma [21], translated into Spanish. Each
subject performed baseline spirometry according to ATS
recommendations [16], using a Collins Survey Tach Spi-
rometer (Warren Collins, Braintree, MA, USA). Follow-
ing baseline spirometry, subjects received 200 μg of
albuterol. Spirometry was repeated after 15 minutes.
iCAP cohort
The i2b2 Crimson Asthma Project (iCAP) consists of
Partners Healthcare System, Inc. (Boston, MA) patients
who were selected based on extracted de-identified elec-
tronic medical record (EMR) data and whose DNA was
obtained via discarded clinical samples. The collection
and study of this data was approved by the Institutional
Review Board of Partners Healthcare System. Asthmatic
and non-asthmatic Partners Healthcare patients were
identified on the basis of International Classification of
Diseases, Ninth Revision (ICD-9) codes for asthma (i.e.
those beginning with 493) [22,23]. DNA was obtained
from discarded clinical blood samples via the Crimson
Project http://www.crimsonproject.org, which identifies
discarded Partners Healthcare clinical samples using
medical record numbers obtained from the EMR query.
For this study, to further ensure that cases truly had
asthma, cases (n = 223) were defined as those patients
whose EMRs contained an asthma ICD-9 code and
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whose medication history included usage of at least one
beta-agonist or inhaled corticosteroid. Controls (n =
858) were selected as those patients who had been seen
in the three years prior to blood collection in at least
one of over 850 outpatient clinics but did not have any
asthma ICD-9 codes. All patients are white. Using a
panel of 187 intergenic SNPs selected randomly
throughout the genome[24], and a set of 248 ancestry
informative markers[25], we evaluated this cohort for
evidence of population stratification. The random panel
of 187 SNPs had an association c2 187 df = 168.7, corre-
sponding to a p-value of 0.83. Repeat association testing
with adjustment for EIGENSTRAT-derived principal
components[26] yielded similar results to the unadjusted
results (r2 = 0.95 between corrected and uncorrected
association statistics), confirming no significant evidence
of population stratification in the iCAP cohort.
Genotyping and Quality Control
rs5743836 genotyping was performed using a custom
design TaqMan 5’®3’ assay (ABI, Foster City, California)
with the following sequences: Forward primer:
GCCTTGGGATGTGCTGTTC; Reverse primer: CAGA-
GACATAATGGAGGCAAAGGA; VIC Probe: CCTGAA
AACTCCC; FAM Probe: CTGGAAACTCCC. The PCR
profile consisted of an initial denaturation step at 95°C
for 10 min followed by 40 amplification cycles at 95°C for
30 s each. For the PCR reaction, ABI TaqMan Universal
PCR Master Mix was used with 6.25 ng of DNA per sam-
ple. ABI 7900 Prism was used for imaging.
TLR9 mRNA expression data was extracted from gen-
ome-wide gene expression microarray profiles (Human-
Ref8 v2 BeadChip (Illumina, San Diego, CA)) derived
from peripheral blood CD4+ lymphocyte RNA samples
in a subset of 200 CAMP participants, as previously
reported[27]. TLR9 is assayed on the HumanRef8 v2
array with a 50-mer oligonucleotide with sequence 5’-
CAGGGACAACCACCACTTCTATAACCG-
GAACTTCTGC CAGGGACCCACGG-3’, which maps
to the terminal coding sequence of the TLR9 reference
sequence (NM_017442).
Statistical Analysis
Family based association testing (FBAT) was performed
using PBAT as implemented in HelixTree version 6.4.3
(Golden Helix, Bozeman, Mont)[28]. TLR9-by-vitamin
D level interactions were tested using the family-based
association tests of interaction (FBATIs) implemented in
PBAT[29]. PLINK[30] was utilized for population-based
association testing and to derive the transmitted to
untransmitted ratios. PLINK was also used for allelic
association testing (c2) in the case-control study (iCAP).
All analyses were performed assuming an additive
genetic model.
In CAMP, tests of association with baseline lung func-
tion were adjusted for age, sex, and height. Tests of
association with all other baseline outcomes were
adjusted for age and sex, and all tests for outcomes at
the 4 year follow-up time point were also adjusted for
treatment group (inhaled steroids vs. placebo or nedo-
cromil). In the population-based analyses in CAMP, we
adjusted for population stratification using the top four
principal components as derived from genome-wide
SNP genotype data[31] using EIGENSTRAT (EIGEN-
SOFT Version 2.0)[26]. SAS version 9.1 (SAS Institute,
Cary, NC)was used to manage and analyze the data. We
calculated a combined p value (first for all three cohorts
and then for the two cohorts of children) using Fisher’s
exact test[32,33].
Transient transfection and luciferase assay
Two TLR9 promoter sequences (from -632 to +619)
including the SNP of interest (-1237C/T or rs5743836)
were amplified by PCR from human genomic DNA and
cloned into a pGL3 basic vector at a KpnI and HindIII
site. The primers used for PCR were: 5’ - GGG GTA
CCC CGA GGG GTC ATA TGA GAC TTG GGG
GAG TTT TCA - 3’ for the 1.2KT and 5’-GGG GTA
CCC CGA GGG GTC ATA TGA GAC TTG GGG
GAG TTT CCA-3’ for the1.2KC promoter. The same
reverse primer for both promoters was used: 5’ - CCC
AAG CTT GCT GGG CTT CTC CAG AGG GT - 3’.
For the luciferase reporter assay, 293 cells were seeded
into a 12-well plate one day prior to transfection.
300 ng promoter or pGL3 basic vector and 10 ng beta-
gal plasmid were transiently transfected into 293 cells
using Fugene 6 (Roche Diagnostics, Indianapolis, IN)
according to the manufacturer’s protocol. 12 hours post
transfection, 1,25-dihydroxyitamin D3 (Enzo Life
Sciences, Farmingdale, NY) was added into cells at var-
ious concentrations for an additional 48 hours. Cells
were then lysed in 100 ul reporter lysis buffer (Promega,
Madison, WI) and the luciferase activity in 50 ul of ali-
quots of cell lysates was measured using Luciferase Assay
System (Promega, Madison, WI) according to the manu-
facturer’s protocol. To monitor the transfection effi-
ciency, a beta-galactosidase assay was conducted using
the same lysate according to the published protocol[34].
All constructs were sequenced before transfection and
each experiment was independently repeated four times
with triplicate wells for each transfection reaction.
Results
TLR9 promoter polymorphism genotyping
The TLR9 promoter region SNP rs5743836 was geno-
typed in 910 families (n = 2261 subjects) in CAMP, in
616 families (n = 1737 subjects) in Costa Rica, and
in 1081 subjects from iCAP (223 cases, 858 controls). In
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CAMP, the genotype quality was high, with a 99.4%
completion rate, only one parent-child genotype incon-
sistency, and perfect concordance upon replicate geno-
typing of a random 5% subset. In Costa Rica and iCAP,
genotype quality was also high with a 98% overall pass
rate, perfect concordance upon replicate genotyping of a
random 6% subset and only 1 discordant result.
Given the relatively small sample sizes of the nonwhite
ethnic groups in CAMP and to avoid false association
caused by population stratification, association analyses
were restricted to 711 Caucasian probands and their
families. Phenotypic characteristics of the Caucasian
children from CAMP as well as baseline characteristics
of the Costa Rica cohort and iCAP cohorts are shown in
Table 1. The minor allele frequency (MAF) for the C
allele was 18% in CAMP, 10% in Costa Rica and 15% in
iCAP. In all three cohorts parental or control genotypes
were in Hardy-Weinberg equilibrium at this locus
(CAMP p = 0.29, CR p = 0.78, iCAP p = 0.27).
Association testing of TLR9 promoter region
polymorphism and asthma
Though there was a trend towards over-transmission of
the minor allele (C) from parent to asthmatic offspring in
the CAMP cohort, (transmitted to untransmitted ratio
[T:U] of 136:112, ratio of 1.21 for the C allele), the asso-
ciation was not statistically significant (FBAT p = 0.14).
There was no trend towards an association in either
Costa Rica (FBAT p = 0.77) or iCAP (c2 p = 0.83); see
Table 2. Using Fisher’s exact test, we calculated a com-
bined p value first for all three cohorts together, and
separately for the two childhood cohorts; neither of these
values was statistically significant (p = 0.57 for all three,
p = 0.35 for the two childhood cohorts).
Moreover, with the exception of post-bronchodilator
measures of lung function (see below), no associations
were noted with intermediate phenotypes analyzed in
CAMP - including bronchodilator response to albuterol,
airways responsiveness, total IgE, skin prick tests for
common aeroallergens, and blood eosinophil counts -
suggesting that TLR9 genotype is not a major determi-
nant of asthma in the CAMP cohort.
Association of TLR9 was noted with post-bronchodi-
lator lung function measures (FEV1 and FVC) at the
4-year follow-up time point in CAMP, with each addi-
tional copy of the minor allele associated with higher
lung function (p = 0.003 and p = 0.008, respectively).
The observed associations were robust to multivariate
adjustment for age, height, sex and treatment arm.
Similar nominal associations were noted when mod-
eled using population-based approaches (p = 0.009 and
p = 0.01, respectively; Figure 1). However, neither the
family- nor population-based tests were significant
after adjustment for multiple comparisons, and the
small actual difference in values was of uncertain clini-
cal significance. Associations were noted only with
year 4 measurements, but not with baseline measures,
and were not replicated in the Costa Rica cohort (data
not shown) raising questions about the importance of
Table 1 Baseline characteristics in each cohort
CAMP Costa Rica iCAP
Mean (SD)
Cases Controls
N 711 616 223 858
Age 8.8 (2.1) 9.0 (1.8) 25.5 (7.0) 26.1 (5.3)
Sex (N, % male) 416 (59%) 370 (60%) 43 (19%) 136 (16%)
Baseline post-bronchodilator FEV1 1.82 (0.5) 1.83 (0.5)
baseline post-bronchodilator FEV1 percent-predicted 104 (12.6) 104 (16.1)
Baseline post-bronchodilator FVC 2.15 (0.63) 2.14 (0.57)
Baseline post-bronchodilator FVC percent-predicted 107 (12.6) 109 (15.8)
Post-bronchodilator FEV1 at 4 yr follow up 2.79 (0.79)
Post-bronchodilator FEV1 at 4 yr follow up percent predicted 103 (12.6)
Post-bronchodilator FVC at 4 yr follow up 3.35 (0.98)
Post-bronchodilator FVC at 4 yr follow up percent predicted 107 (12.2)
rs5743836 C: minor allele T: major allele
Minor allele frequency 18% 10% 15%
Table 2 Results for association testing with rs5743836
and asthma affection status
Cohort Sample size1 p value2
CAMP 208 0.14
Costa Rica 185 0.77
iCAP cohort cases: 223 ctrls: 858 0.83
1Number of informative families in CAMP and Costa Rica; N for iCAP.
2FBAT in CAMP and Costa Rica, chi-square test in iCAP.
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the observed associations. Moreover, the TLR9 promo-
ter variant was not associated with asthma exacerba-
tions over the 4 years of the clinical trial (defined as
emergency room visits, hospitalizations or prednisone
bursts).
Interaction with Vitamin D
Based on prior knowledge of the interaction of TLR9
with vitamin D[12], and the relationship to induction of
IL-10 producing Tregs, we tested for an interaction
between the SNP and vitamin D levels in this cohort.
We did not find a significant association with this SNP
and vitamin D insufficiency (defined as ≤30 ng/ml) with
any lung function measures (p = 0.44-0.98 for interac-
tion), nor with the other outcomes tested including
those listed above. We looked at vitamin D levels as a
continuous variable as well and found similar results
(data not shown).
Functional studies of TLR9 promoter region genotype
To test whether rs5743836 genotype affects promoter
activity of the TLR9 gene, we cloned two promoters
containing either the TT or CC genotype into firefly
luciferase reporter vectors; the two promoters were
designated as1.2KT and 1.2KC respectively. Promoter
activity was assessed using the luciferase assay system.
After standardization with beta-gal, the promoter con-
taining the T variant (1.2KT) showed lower activity than
the promoter containing the C variant (9.3 fold versus
11.7 fold, P = 0.003)
(Figure 2A). We further investigated whether the
active form of vitamin D (1,25(OH)2D3) affects promoter
activity of TLR9. After 2 days of treatment with 1,25
(OH)2D3, the change of TLR9 promoter activity was
negligible in 293 cells (Figure 2B).
Because the CC genotype was associated with
higher promoter activity, we analyzed TLR9 mRNA
expression levels from CD4+ lymphocytes from a sub-
set of 200 non-Hispanic white CAMP asthmatics.
Expression levels were not significantly associated
with rs5743836 genotype (FBAT p = 0.80, population-
based p = 0.38).
Discussion
Based on previous studies by our group[5], and knowl-
edge of a potential interaction between TLR9 and vita-
min D[12,35], we examined possible associations
between rs5743836, a SNP in the promoter region of
TLR9, and asthma in three different cohorts of asth-
matics, as well as with related quantitative phenotypes
in the CAMP cohort. We also looked for an interaction
between this SNP and vitamin D levels, and performed
functional studies using this SNP. Although there was a
trend towards over transmission of the C allele in chil-
dren with asthma in the CAMP cohort, this was not sta-
tistically significant; nor was it found in the other two
cohorts of asthmatics. We found a weak association
between this SNP and lung function measures in CAMP
at the 4-year follow-up point in both the family- and
population-based analyses. However this was no longer
statistically significant once corrected for multiple com-
parisons, was only observed at one of two time points
studied, and was not replicated in the Costa Rican
cohort. We found no other significant associations
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Figure 1 Results from population-based analysis of rs5743836 genotype and lung function measures in CAMP. Median values (X) and
interquartile range for FEV1 and FVC at the 4 year follow up timepoint by rs5743836 genotype in CAMP.
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between this SNP and any other intermediate pheno-
types tested, nor was there an interaction with vitamin
D levels. Though we demonstrated in vitro evidence
that the rs5743836 CC genotype confers increased
expression of TLR9, this association was not observed in
an epidemiological context: the variant was not asso-
ciated with CD4+ lymphocyte TLR9 expression in the
CAMP cohort. Together, these data suggest this poly-
morphism does not play a role in susceptibility to
asthma in these three cohorts, nor in the development
of asthma-related phenotypes in CAMP.
Evidence from prior studies suggests that this SNP in
TLR9 could be important in asthma and other inflam-
matory diseases. Our group had previously found the C
allele of this SNP to be associated with asthma in Eur-
opean Americans[5]. Another study showed similar find-
ings in a cohort of Tunisian children with asthma, with
higher risk conferred by the C allele[6]. The SNP has
been found to be associated with other allergic diseases
such as ABPA in a population from the UK[7]; one of
the diagnostic criteria for ABPA is the presence of
asthma. An association was also found in a study of ato-
pic eczema in Germans[8], though it was the T allele
that was over transmitted in affected individuals. In
addition, it has been found in association with IBD
[9-11,36] as well as with Hodgkin’s disease[37]
susceptibility to tuberculosis infection[38] and viral set
point in HIV[39].
Furthermore, other emerging data about TLR9 more
generally offers compelling evidence for its role in mod-
ulation of inflammatory and allergic diseases, and a pos-
sible route to therapy. TLR9 knockout mice have lower
airways hyperresponsiveness in a model of fungal
asthma[40]. Additionally, the ligand for TLR9 (CpG) is
being investigated in animal models and some human
studies as an adjuvant for immunotherapy of allergic
diseases including allergic rhinitis and asthma[3,41-43].
Although the exact mechanism of benefit is unknown,
the inhibition of TH2 cytokines may be achieved
through induction of TH1-type cytokines such as IL12,
IFNa, IFNg, or through other mechanisms[44,45]
including induction of IL-10 or indoleamine 2,3-dioxy-
genase activity and Treg cells[46,47]. The biologic effects
of TLR9 activation on allergic inflammation are likely
highly complex and merit further investigation.
However, conflicting studies showed no association
with this SNP or others in TLR9 in similar diseases. No
association was found with atopy in a second German
cohort[48]. The rs5743836 polymorphism was not
observed in a sequencing survey of 32 Japanese asth-
matics. Other TLR9 variants that were observed in that
cohort showed no associations with asthma affection
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Figure 2 TLR9 promoter activity in HEK 293 cells. A. Higher TLR9 promoter activity was associated with CC allelic variant at rs5743836. HEK
293 cells were transiently transfected with reporter constructs with TLR9 promoter containing either genotype TT (1.2KTT) or CC (1.2KCC) at
rs5743836. 48 hours post transfection, cells were lysed for luciferase activity and normalized to b-gal readings. Luciferase activity from pGL3-basic
vector transfected cells was defined as 1. Standard deviation is from triplicate wells. Similar results were obtained from at least three
independent experiments. B. Vitamin D has no significant effect on the promoter activity of TLR9. HEK 293 cells were transfected with 1.2KTT
and 1.2KCC TLR9 promoter. 12 hours post transfection, cells were treated with active form of Vitamin D (1,25(OH)2D3) at various concentrations.
48 hours later, promoter activity was analyzed by luciferase assay. Standard deviation is from triplicate wells of each transfection.
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status or serum IgE level[49]. Similar studies in Cauca-
sian populations from Canada and Australia[50], and in
French Europeans[51] also failed to observe associations
with asthma. TLR9 variation does not appear to have
association with either SLE[52-54] or Behcet’s disease
[55,56].
The strengths of our study include the use of three
different asthmatic populations: two in children and one
in adults. In addition, our analysis of intermediate phe-
notypes was carried out in CAMP, a well-characterized
population of asthmatics with extensive phenotyping
data including lung function measures (spirometry,
methacholine challenge results, bronchodilator respon-
siveness), skin test results, IgE and eosinophil levels, and
data on exacerbation frequency. We used both a family-
based association test, which is robust to population
stratification, as well as population-based testing, which
is more powerful than family-based testing. Population
based tests were adjusted for population stratification
using principal components[26]. The addition of a high
quality assessment of functionality with this SNP
strengthens any possibility of association.
There are several possible reasons for discrepant
results among studies of association between this SNP
and asthma. These include sample size, differing pheno-
type definitions, differing populations, population strati-
fication, differing linkage disequilibrium patterns, and
genetic and environmental heterogeneity. Our study
includes two well-characterized cohorts of children with
asthma, and a cohort of adult asthmatics. Asthmatics of
differing severity or age may be a different enough phe-
notype to lead to different results from association test-
ing. We may have been limited in power to detect an
association given the sample sizes in the three cohorts.
In addition, the population-based association testing
performed in CAMP examined variability among indivi-
duals within the cohort of asthmatics; if we had com-
pared our cohort to a well-matched control group,
testing intermediate phenotypes may have revealed an
association. Prior studies of this SNP and asthma were
small and were not controlled for population stratifica-
tion. In the Tunisian study, significant results from the
case-control analysis were not reproduced when families
were analyzed using the transmission disequilibrium test
(TDT) which is robust to population stratification, sug-
gesting positive results from the case-control portion
may have been spurious.
We detected a moderate increase in promoter activity
associated with the CC genotype. This could be
explained by the possible creation of an NF-B binding
site due to a change to the C allele which has been
shown in in silico analysis[57]. Higher promoter activity
with the T allele has been found in one previous study
[8] though more recently another study showed higher
activity with the C allele, consistent with our findings
[58]. Since we found no correlation between rs5743836
genotype and TLR9 mRNA level in a subset of the
CAMP population, we cannot exclude the existence of
other functional variants in this region that interact with
rs5743836 to regulate the expression of TLR9. Given the
complexity of gene regulation in vivo, the lack of asso-
ciation with TLR9 expression levels is not surprising.
Conclusions
In summary, we examined associations between a SNP
in the promoter of TLR9, rs5743836, and asthma in
three unrelated cohorts of asthmatics, and found no sta-
tistically significant associations after correcting for mul-
tiple testing. In addition, we performed functional
studies which showed that this SNP does appear to have
functional significance. Despite these in vitro findings,
our results suggest that this polymorphism does not
play a significant role in asthma susceptibility or asthma
related phenotypes. This does not rule out a role for the
gene in asthma. Despite these negative results, future
studies to further elucidate the effects of TLR9 activa-
tion in modulating inflammation, as well as the possible
role of TLR9 agonists in therapy for allergic and inflam-
matory diseases are warranted.
Funding
CAMP: The CAMP Genetics Ancillary Study is sup-
ported by U01 HL075419, U01 HL65899, P01
HL083069 and T32 HL07427 from the National Heart,
Lung and Blood Institute, National Institutes of Health
(NIH/NHLBI). The expression work is supported by
grant R01 HL086601 from the (NIH/NHLBI). Dr. Liton-
jua is supported by R01 AI056230. Dr. Lazarus is sup-
ported by R01 HG0036.
Costa Rica: The Genetics of Asthma in Costa Rica
study is supported by NIH grants HL04370 and
HL66289.
iCAP: This work was supported by the NIH grant
5U54LM008748-02 (National Centers for Biomedical
Computing).
Acknowledgements
We thank all subjects and their families for their past and ongoing
participation in the CAMP and the Genetics of Asthma in Costa Rica studies.
We acknowledge the CAMP investigators and research team, supported by
NHLBI, for collection of CAMP Genetic Ancillary Study data. We thank Drs.
Andy Liu and Stanley Szefler (National Jewish, Denver CO), Nadia Hansel,
Greg Diette and Franklin Adkinson (Johns Hopkins, Baltimore MD), and Karen
DeMuth, Robert Strunk and Mario Castro (Washington University, St. Louis
MO) and Anne Fuhlbrigge (Brigham and Women’s Hospital, Boston MA) for
their assistance in collection of CD4+ lymphocytes and RNA extraction.
Special thanks to Anne Plunkett, Teresa Concordia, Debbie Bull, Denise
Rodgers, and D. Sundstrom for their assistance with sample collection; to
Huiqing Yin-DeClue, Ph.D, Michael McLane and Chris Allaire for their
assistance with T cell isolations and RNA preparation; and to Ankur Patel for
his assistance running the microarrays.
Lange et al. BMC Medical Genetics 2011, 12:26
http://www.biomedcentral.com/1471-2350/12/26
Page 7 of 9
All work on data collected from the CAMP Genetic Ancillary Study and the
Costa Rica study was conducted at the Channing Laboratory of the Brigham
and Women’s Hospital under appropriate policies and human subject
protections.
We thank Scott Weiss for his advice in the preparation of this manuscript.
Author details
1Channing Laboratory, Brigham and Women’s Hospital and Harvard Medical
School, 181 Longwood Avenue, Boston, MA, 02115, USA. 2Division of
Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and
Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. 3Division
of Pediatric Pulmonology, Hospital Nacionál de Niños, Calle 20, San José,
Costa Rica. 4Division of Pediatric Pulmonary Medicine, Allergy and
Immunology, Children’s Hospital of Pittsburgh of the University of Pittsburgh
Medical Center, One Children’s Hospital Drive, 4401 Penn Ave., Pittsburgh,
PA, 15224, USA. 5Department of Asthma, Allergy and Respiratory Science,
King’s College London, Guy’s Hospital, Great Maze Pond, London SE1 9RT,
UK.
Authors’ contributions
NEL contributed to the study design, performed the analyses and drafted
the manuscript. XZ performed the functional studies and contributed to the
manuscript writing. JL-S contributed to the study design and statistical
analysis. BEH contributed to the statistical analysis. RL contributed to the
statistical analysis. MSQ contributed to the study design and data collection.
LA contributed to the study design and data collection. JCC contributed to
the study design and provided critical revision of the manuscript. CMH
contributed to the data analysis and interpretation. BAR contributed to the
study design and provided critical revision of the manuscript. AAL
contributed to the study design and provided critical revision of the
manuscript. All authors read and approved the final manuscript.
Competing interests
Dr. Soto-Quiros reports receiving lecture fees from AstraZeneca,
GlaxoSmithKline, and Merck Sharp & Dohme; Dr. Avila reports receiving
lecture fees from AstraZeneca and Merck Sharp & Dohme; Dr. Hawrylowicz
reports receiving lecture honoraria/fees from Merck. Dr. Raby reports
receiving lecture fees from Novartis Pharmaceuticals for in-house
educational services. No other authors have any competing interests to
declare.
Received: 4 August 2010 Accepted: 15 February 2011
Published: 15 February 2011
References
1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma:
executive summary of the GINA Dissemination Committee report. Allergy
2004, 59(5):469-478.
2. Schroder NW, Maurer M: The role of innate immunity in asthma: leads
and lessons from mouse models. Allergy 2007, 62(6):579-590.
3. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev
Drug Discov 2006, 5(6):471-484.
4. Pasare C, Medzhitov R: Control of B-cell responses by Toll-like receptors.
Nature 2005, 438(7066):364-368.
5. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, Kwiatkowski DJ,
Silverman EK, Martinez F, Weiss ST: Single-nucleotide polymorphisms in
the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage
disequilibrium, and haplotypes in three U.S. ethnic groups and
exploratory case-control disease association studies. Genomics 2003,
81(1):85-91.
6. Lachheb J, Dhifallah IB, Chelbi H, Hamzaoui K, Hamzaoui A: Toll-like
receptors and CD14 genes polymorphisms and susceptibility to asthma
in Tunisian children. Tissue Antigens 2008, 71(5):417-425.
7. Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW, Rodrigues F:
Polymorphisms in toll-like receptor genes and susceptibility to
pulmonary aspergillosis. J Infect Dis 2008, 197(4):618-621.
8. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, Hagemann T,
Diaz-Lacava A, Baurecht HJ, Klopp N, et al: Putative association of a TLR9
promoter polymorphism with atopic eczema. Allergy 2007,
62(7):766-772.
9. Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW: TLR2,
TLR4 and TLR9 polymorphisms and Crohn’s disease in a New Zealand
Caucasian cohort. J Gastroenterol Hepatol 2007, 22(11):1760-1766.
10. Torok HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, Klein W,
Lohse P, Ochsenkuhn T, Folwaczny M, et al: Epistasis Between Toll-Like
Receptor-9 Polymorphisms and Variants in NOD2 and IL23R Modulates
Susceptibility to Crohn’s Disease. Am J Gastroenterol 2009.
11. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C:
Crohn’s disease is associated with a toll-like receptor-9 polymorphism.
Gastroenterology 2004, 127(1):365-366.
12. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ,
Corrigan CJ, Hickman E, Brown Z, Hawrylowicz CM: Ligation of TLR9
induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin
D3 abrogates regulatory function. J Clin Invest 2009, 119(2):387-398.
13. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and
the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
14. The Childhood Asthma Management Program (CAMP): design, rationale,
and methods. Childhood Asthma Management Program Research
Group. Control Clin Trials 1999, 20(1):91-120.
15. Long-term effects of budesonide or nedocromil in children with asthma.
The Childhood Asthma Management Program Research Group. N Engl J
Med 2000, 343(15):1054-1063.
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, et al: Standardisation of
spirometry. Eur Respir J 2005, 26(2):319-338.
17. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL: Determination of
vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin
Chem 1993, 39(3):529-533.
18. Hollis BW, Napoli JL: Improved radioimmunoassay for vitamin D and its
use in assessing vitamin D status. Clin Chem 1985, 31(11):1815-1819.
19. Hunninghake GM, Soto-Quiros ME, Avila L, Ly NP, Liang C, Sylvia JS,
Klanderman BJ, Silverman EK, Celedon JC: Sensitization to Ascaris
lumbricoides and severity of childhood asthma in Costa Rica. J Allergy
Clin Immunol 2007, 119(3):654-661.
20. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C:
Worldwide trends in the prevalence of asthma symptoms: phase III of
the International Study of Asthma and Allergies in Childhood (ISAAC).
Thorax 2007, 62(9):758-766.
21. Blumenthal MN, Banks-Schlegel S, Bleecker ER, Marsh DG, Ober C:
Collaborative studies on the genetics of asthma–National Heart, Lung
and Blood Institute. Clin Exp Allergy 1995, 25(Suppl 2):29-32.
22. Himes BE, Dai Y, Kohane IS, Weiss ST, Ramoni MF: Prediction of chronic
obstructive pulmonary disease (COPD) in asthma patients using
electronic medical records. J Am Med Inform Assoc 2009, 16(3):371-379.
23. Zeng QT, Goryachev S, Weiss S, Sordo M, Murphy SN, Lazarus R: Extracting
principal diagnosis, co-morbidity and smoking status for asthma
research: evaluation of a natural language processing system. BMC Med
Inform Decis Mak 2006, 6:30.
24. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect
population stratification in association studies. Am J Hum Genet 1999,
65(1):220-228.
25. Price AL, Butler J, Patterson N, Capelli C, Pascali VL, Scarnicci F, Ruiz-
Linares A, Groop L, Saetta AA, Korkolopoulou P, et al: Discerning the
ancestry of European Americans in genetic association studies. PLoS
Genet 2008, 4(1):e236.
26. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D:
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 2006, 38(8):904-909.
27. Chu JH, Weiss ST, Carey VJ, Raby BA: A graphical model approach for
inferring large-scale networks integrating gene expression and genetic
polymorphism. BMC Syst Biol 2009, 3:55.
28. Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM: PBAT: tools for
family-based association studies. Am J Hum Genet 2004, 74(2):367-369.
29. Lake SL, Laird NM: Tests of gene-environment interaction for case-parent
triads with general environmental exposures. Ann Hum Genet 2004, 68(Pt
1):55-64.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, et al: PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet
2007, 81(3):559-575.
Lange et al. BMC Medical Genetics 2011, 12:26
http://www.biomedcentral.com/1471-2350/12/26
Page 8 of 9
31. Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P,
Strachan DP, Wilk JB, Willis-Owen SA, Klanderman B, Lasky-Su J, et al:
Genome-wide association analysis identifies PDE4 D as an asthma-
susceptibility gene. Am J Hum Genet 2009, 84(5):581-593.
32. Fisher RAS: Statistical Methods for Research Workers. New York: Hafner
Press;, 14 1970.
33. Won S, Morris N, Lu Q, Elston RC: Choosing an optimal method to
combine P-values. Stat Med 2009, 28(11):1537-1553.
34. Baron RM, Carvajal IM, Liu X, Okabe RO, Fredenburgh LE, Macias AA,
Chen YH, Ejima K, Layne MD, Perrella MA: Reduction of nitric oxide
synthase 2 expression by distamycin A improves survival from
endotoxemia. J Immunol 2004, 173(6):4147-4153.
35. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF:
Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression
and Toll-like receptor 9-induced IL-6 production in human monocytes.
Rheumatology (Oxford) 2010.
36. Lammers KM, Ouburg S, Morre SA, Crusius JB, Gionchett P, Rizzello F,
Morselli C, Caramelli E, Conte R, Poggioli G, et al: Combined carriership of
TLR9-1237C and CD14-260T alleles enhances the risk of developing
chronic relapsing pouchitis. World J Gastroenterol 2005, 11(46):7323-7329.
37. Mollaki V, Georgiadis T, Tassidou A, Ioannou M, Daniil Z, Koutsokera A,
Papathanassiou AA, Zintzaras E, Vassilopoulos G: Polymorphisms and
haplotypes in TLR9 and MYD88 are associated with the development of
Hodgkin’s lymphoma: a candidate-gene association study. J Hum Genet
2009.
38. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, Myers JL, Estevan R,
Patillo SG, Olesen R, Tacconelli A, et al: Variants in toll-like receptors 2 and
9 influence susceptibility to pulmonary tuberculosis in Caucasians,
African-Americans, and West Africans. Hum Genet 2009.
39. Pine SO, McElrath MJ, Bochud PY: Polymorphisms in toll-like receptor 4
and toll-like receptor 9 influence viral load in a seroincident cohort of
HIV-1-infected individuals. AIDS 2009, 23(18):2387-2395.
40. Ramaprakash H, Ito T, Standiford TJ, Kunkel SL, Hogaboam CM: Toll-like
receptor 9 modulates immune responses to Aspergillus fumigatus
conidia in immunodeficient and allergic mice. Infect Immun 2009,
77(1):108-119.
41. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL,
Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, et al:
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for
allergic rhinitis. N Engl J Med 2006, 355(14):1445-1455.
42. Kline JN, Krieg AM: Toll-like receptor 9 activation with CpG
oligodeoxynucleotides for asthma therapy. Drug News Perspect 2008,
21(8):434-439.
43. Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of
innate immunity with Toll-like receptor agonists and antagonists. Nat
Med 2007, 13(5):552-559.
44. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR: CpG
oligodeoxynucleotides do not require TH1 cytokines to prevent
eosinophilic airway inflammation in a murine model of asthma. J Allergy
Clin Immunol 1999, 104(6):1258-1264.
45. Tversky JR, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT:
Subcutaneous allergen immunotherapy restores human dendritic cell
innate immune function. Clin Exp Allergy 40(1):94-102.
46. Constabel H, Stankov MV, Hartwig C, Tschernig T, Behrens GM: Impaired
lung dendritic cell migration and T cell stimulation induced by
immunostimulatory oligonucleotides contribute to reduced allergic
airway inflammation. J Immunol 2009, 183(5):3443-3453.
47. Kline JN: Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am
Thorac Soc 2007, 4(3):283-288.
48. Berghofer B, Frommer T, Konig IR, Ziegler A, Chakraborty T, Bein G,
Hackstein H: Common human Toll-like receptor 9 polymorphisms and
haplotypes: association with atopy and functional relevance. Clin Exp
Allergy 2005, 35(9):1147-1154.
49. Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, Arinami T:
An association study of asthma and total serum immunoglobin E levels
for Toll-like receptor polymorphisms in a Japanese population. Clin Exp
Allergy 2004, 34(2):177-183.
50. Daley D, Lemire M, Akhabir L, Chan-Yeung M, He JQ, McDonald T,
Sandford A, Stefanowicz D, Tripp B, Zamar D, et al: Analyses of
associations with asthma in four asthma population samples from
Canada and Australia. Hum Genet 2009, 125(4):445-459.
51. Smit LA, Siroux V, Bouzigon E, Oryszczyn MP, Lathrop M, Demenais F,
Kauffmann F: CD14 and toll-like receptor gene polymorphisms, country
living, and asthma in adults. Am J Respir Crit Care Med 2009,
179(5):363-368.
52. De Jager PL, Richardson A, Vyse TJ, Rioux JD: Genetic variation in toll-like
receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis
Rheum 2006, 54(4):1279-1282.
53. Demirci FY, Manzi S, Ramsey-Goldman R, Kenney M, Shaw PS, Dunlop-
Thomas CM, Kao AH, Rhew EY, Bontempo F, Kammerer C, et al: Association
study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9)
polymorphisms in systemic lupus erythematosus. J Rheumatol 2007,
34(8):1708-1711.
54. Hur JW, Shin HD, Park BL, Kim LH, Kim SY, Bae SC: Association study of
Toll-like receptor 9 gene polymorphism in Korean patients with systemic
lupus erythematosus. Tissue Antigens 2005, 65(3):266-270.
55. Ito A, Ota M, Katsuyama Y, Inoko H, Ohno S, Mizuki N: Lack of association
of Toll-like receptor 9 gene polymorphism with Behcet’s disease in
Japanese patients. Tissue Antigens 2007, 70(5):423-426.
56. Ben Dhifallah I, Lachheb J, Houman H, Hamzaoui K: Toll-like-receptor gene
polymorphisms in a Tunisian population with Behcet’s disease. Clin Exp
Rheumatol 2009, 27(2 Suppl 53):S58-62.
57. Hamann L, Glaeser C, Hamprecht A, Gross M, Gomma A, Schumann RR:
Toll-like receptor (TLR)-9 promotor polymorphisms and atherosclerosis.
Clin Chim Acta 2006, 364(1-2):303-307.
58. Ng MT, van ‘t Hof R, Crockett JC, Hope ME, Berry S, Thomson J,
McLean MH, McColl KE, El-Omar EM, Hold GL: Increase in NF-{kappa}B
binding affinity of the C allelic variant of the Toll-like receptor 9 -1237T/
C polymorphism is associated with Helicobacter pylori induced gastric
disease. Infect Immun 2009.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/26/prepub
doi:10.1186/1471-2350-12-26
Cite this article as: Lange et al.: Comprehensive genetic assessment of a
functional TLR9 promoter polymorphism: no replicable association with
asthma or asthma-related phenotypes. BMC Medical Genetics 2011 12:26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lange et al. BMC Medical Genetics 2011, 12:26
http://www.biomedcentral.com/1471-2350/12/26
Page 9 of 9
